Top 10 Pharma Corporate Venture Capital
Rosetta Capital completed a secondary transaction to acquire a portfolio of over 20 North American and European life sciences assets from a Corporate Venture Capital arm of a Top 10 Pharma company. This enabled the Corporate Venture Capital arm to redeploy capital into assets that aligned strategically with the parent company.
Selected exits from the portfolio include the sale of Novimmune to Sobi and the GlycoMimetics and Paratek IPOs on NASDAQ.
Supporting portfolio companies for the next growth phase
Rosetta Capital supported the portfolio companies acquired in the transaction through the growth phase and made several follow-on investments
The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company’s holdings in delivering sustainable value and positive long-term shareholder returns.”
Tim Creed and Ben Wicks
Portfolio Managers at Schroder UK Public Private Trust plc